Real-World Studies
Aromatase Inhibitors vs Tamoxifen and Incident Intracranial Meningioma Risk in Breast Cancer
Wijaya et alCancer Causes & Control

In a propensity score–matched cohort study utilizing the TriNetX Global Collaborative Network of 181 healthcare organizations, investigators evaluated the risk of incident intracranial meningioma in adult breast cancer patients initiating aromatase inhibitors (anastrozole, letrozole, or exemestane) versus tamoxifen between 2010 and 2015 without cross-class exposure. Cohorts were matched 1:1 across 27 covariates, yielding 23,204 patients per group, with 23,110 aromatase inhibitor users and 23,114 tamoxifen users without prior meningioma evaluated for incident outcomes over 1, 2, and 3 years using Cox proportional hazards models.
Aromatase inhibitor initiation was associated with a higher risk of incident meningioma compared with tamoxifen at 1 year (1.51 vs 0.82 per 1,000; hazard ratio [HR] 1.846, 95% CI 1.056–3.227), 2 years (2.64 vs 1.56 per 1,000; HR 1.705, 95% CI 1.129–2.574), and 3 years (3.29 vs 2.29 per 1,000; HR 1.449, 95% CI 1.021–2.058). The absolute risk differences remained modest, recorded at 0.69, 1.08, and 1.00 per 1,000 patients at 1, 2, and 3 years, respectively. The authors concluded that aromatase inhibitor initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma compared to tamoxifen with minimal absolute excess, indicating that findings should not guide endocrine therapy selection but may assist in evaluating newly detected dural-based lesions.
Key Takeaways
- Patients initiating aromatase inhibitors had a higher risk of incident meningioma compared with tamoxifen at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056–3.227), 2 years (2.64 vs 1.56 per 1,000; HR 1.705, 95% CI 1.129–2.574), and 3 years (3.29 vs 2.29 per 1,000; HR 1.449, 95% CI 1.021–2.058).
- Absolute risk differences were small across follow-up intervals (0.69, 1.08, and 1.00 per 1,000 at 1, 2, and 3 years, respectively), supporting that these findings should not alter endocrine therapy selection but may inform the clinical evaluation of new dural-based lesions.
Read the original sourceCancer Causes & Control
